Evidence map›Paper›PMID 41746986›Full record

ArticlePLOS global public health2026

Development of seropositivity to SARS-CoV-2 over the course of the COVID-19 pandemic in adolescents in a longitudinal cohort study in Cebu, Philippines.

Jedas Veronica Daag, Gianne Lariz Magsakay, Silvia Blanco Rivera, Ma Gladys Nicole Daque, Irish Lobitana, Marla Angela Lariana, Kiarah Louise Florendo, Maria Vinna Crisostomo, Ana Coello Escoto, Lakshmanane Premkumar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jedas Veronica DaagInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Gianne Lariz MagsakayInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Silvia Blanco RiveraViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0001-7140-8845
Ma Gladys Nicole DaqueInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Irish LobitanaInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Marla Angela LarianaInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Kiarah Louise FlorendoInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Maria Vinna CrisostomoInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Ana Coello EscotoViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0002-9634-5091
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Rosemary AogoViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Jacqueline DeenInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.
Leah KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0003-1033-6758
Michelle YladeInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, City of Manila, Philippines.ORCID https://orcid.org/0000-0002-2653-4460

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 was first reported in the Philippines in January 2020 and the country experienced several COVID-19 waves. Little is known on the seroprevalence of SARS-CoV-2 among adolescents in a developing country such as the Philippines. In this study, we incorporated testing for acute COVID-19 and SARS-CoV-2 seropositivity in an ongoing dengue study of 9- to 14-year-old participants enrolled in 2017. Acute febrile episodes were detected through active surveillance and a nasopharyngeal swab was obtained for SARS-CoV-2 RT-PCR. Before COVID-19 vaccination was offered, we tested a subset of sera obtained in 2021 for SARS-CoV-2 receptor binding domain (RBD) antibodies. Development of SARS-CoV-2 seropositivity acquired through natural infection and vaccination was conducted by measuring antibodies pre- (2018-2019), early- (2019-2020), and late-pandemic (2022-2023) in those with matched samples. From July 2021-October 2022, we recorded 29 acute febrile illness episodes in the cohort and 17.0% were SARS-CoV-2 RT-PCR positive. In the subset of 499 samples tested for SARS-CoV-2 RBD antibodies in 2021, 30.3% were seropositive. Among these, 4.0% were seropositive in 2018-2019, and 11.0% had seroconverted by 2020. Interestingly, 74.0% experienced antibody waning between 2020 and 2021 sampling. By 2022, 345/499 children received full COVID-19 vaccination and 13/499 was partially vaccinated, with 96.6% SARS-CoV-2 seropositive by late-pandemic sample in 2022-2023. Vaccination and site were predictors of SARS-CoV-2 RBD antibodies. These findings suggest both variation in local transmission over time as well as association of vaccination with the development of SARS-CoV-2 immunity in adolescents in the Philippines.

Identifiers

PMID41746986
PMCPMC12944793

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.